Announcements Trials
Browse Landscape

Status

Recruiting 8Unknown 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Specimen Handling 7Educational Status 7Cisplatin 7Standard of Care 6Interviews as Topic 6Blood Specimen Collection 6Radiotherapy 5Nivolumab 5Chemoradiotherapy 5Carboplatin 5Surgical Procedures, Operative 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Drug Therapy 4lenvatinib 3camrelizumab 3Surveys and Questionnaires 3Practice Guidelines as Topic 3Patient Navigation 3Methods 3Magnetic Resonance Spectroscopy 3Magnetic Resonance Imaging 3Lenalidomide 3Gemcitabine 3Fluorodeoxyglucose F18 3Exercise 3Early Intervention, Educational 3Dexamethasone 3Cytarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × OTHER × olverembatinib × Clear all
NCT07383298 2026-02-03

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

Peking University People's Hospital

Enrolling by invitation
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡